HER-2-Positive Tumors: A Continuously Evolving Field in Cancer Research

Almost 25 years ago, trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), was licensed for the treatment of patients with metastatic HER2-positive breast cancer in the United States of America (USA) [...].

Saved in:

Bibliographic Details
Published in:	Cancers Vol. 15; no. 13; p. 3333
Main Authors:	Hofheinz, Ralf, Lorenzen, Sylvie, Bohlmann, Michael K
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 25-06-2023 MDPI
Subjects:	Antimitotic agents Antineoplastic agents Breast cancer Cancer Cancer research Cancer therapies Care and treatment Chemotherapy Colorectal cancer Conflicts of interest Drugs Epidermal growth factor ErbB-2 protein Esophagus Gastric cancer Kinases Medical prognosis Metastasis Monoclonal antibodies Oncology, Experimental Radiation therapy Response rates Tumors United States > US
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Almost 25 years ago, trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), was licensed for the treatment of patients with metastatic HER2-positive breast cancer in the United States of America (USA) [...].
Bibliography:	SourceType-Scholarly Journals-1 content type line 23 ObjectType-Editorial-2 ObjectType-Commentary-1
ISSN:	2072-6694 2072-6694
DOI:	10.3390/cancers15133333